Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109328
Title:
Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.
Authors:
Alduaij, Waleed; Illidge, Timothy M ( 0000-0003-3191-7324 )
Abstract:
The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Early-phase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients.
Affiliation:
School of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, United Kingdom.
Citation:
Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. 2009, 11 (5):363-70 Curr Oncol Rep
Journal:
Current Oncology Reports
Issue Date:
Sep-2009
URI:
http://hdl.handle.net/10541/109328
DOI:
10.1007/s11912-009-0049-8
PubMed ID:
19679011
Type:
Article
Language:
en
ISSN:
1534-6269
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorAlduaij, Waleeden
dc.contributor.authorIllidge, Timothy Men
dc.date.accessioned2010-08-09T15:00:57Z-
dc.date.available2010-08-09T15:00:57Z-
dc.date.issued2009-09-
dc.identifier.citationRadioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. 2009, 11 (5):363-70 Curr Oncol Repen
dc.identifier.issn1534-6269-
dc.identifier.pmid19679011-
dc.identifier.doi10.1007/s11912-009-0049-8-
dc.identifier.urihttp://hdl.handle.net/10541/109328-
dc.description.abstractThe conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Early-phase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHumans-
dc.subject.meshLymphoma-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleRadioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, United Kingdom.en
dc.identifier.journalCurrent Oncology Reportsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.